- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05533749
Evaluating the Effectiveness of the GILL eHealth Intervention to Improve Physical Health and Lifestyle Behaviours in Patients With Severe Mental Illness (GILL)
September 8, 2022 updated by: Berno van Meijel, Amsterdam UMC, location VUmc
Improving Physical Health and Lifestyle Behaviors in Patients With Serious Mental Illness: a Cluster Randomized Controlled Trial on the Effectiveness of the Nurse-led GILL eHealth Intervention
The aim of this study is to evaluate the effectiveness of the nurse-led GILL (Gezondheid in Lichaam en Leefstijl) eHealth intervention in patients with serious mental illness (SMI), compared to usual care.
Expected is that the GILL eHealth intervention will be more effective than usual care in improving physical health and lifestyle behaviors.
To evaluate this, we will perform a cluster randomized controlled trial with an embedded process evaluation of the implementation of the GILL intervention.
246 adult patients with serious mental illness and a body mass index of 27 or higher (overweight/obesity) will be included.
The GILL eHealth intervention consists of two complementary modules for (a) somatic screening and (b) lifestyle promotion, resulting in a personalized somatic treatment and lifestyle plan.
Trained mental health nurses and clinical nurse specialists will implement the intervention within the multidisciplinary treatment context, and will guide and support the patients in the promotion of their somatic health, including cardiometabolic risk management.
The intervention will be compared to usual care, which includes treatment according to national guidelines.
The outcome measures will be metabolic syndrome severity (primary), fitness, physical activity, lifestyle behaviors, quality of life, recovery, psychosocial functioning, health related self-efficacy and health care utilization after 1 year.
The process evaluation focuses on the feasibility of the eHealth intervention, its acceptability for patients and health care providers (mainly mental health nurses and clinical nurse specialists), and barriers/facilitators to implementation.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
246
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Meike M Hoogervorst
- Phone Number: +31629680823
- Email: m.m.hoogervorst@amsterdamumc.nl
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Meet the criteria of severe mental illness
- Aged from 18 to 65 years
- Body mass index (BMI) ≥ 27
- Access and ability to use internet and mobile device
- Able and willing to sign informed consent
Exclusion Criteria:
- Contra-indications (to be assessed by the treating physician/psychiatrist) for participation due to acute psychiatric crisis or severe somatic diseases
- Subjects with a cognitive impairment sufficient to interfere with their ability to provide informed consent, complete study questionnaires, or participate in the intervention
- Pregnant or breastfeeding women at the time of inclusion
- Subject not able to communicate in the Dutch language
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GILL eHealth module
Patients will perform the GILL eHealth.
This eHealth contains two modules focusing on systematic somatic screening and lifestyle behaviors.
|
The aim of the successfully pilot-tested GILL eHealth intervention is to support mental health nurses and clinical nurse specialists in structured somatic screening and lifestyle promotion.
The GILL eHealth intervention consists of two parts.
Part one is OurGILL which focuses on systematic somatic screening and provides an overview of all somatic abnormalities.
It promotes the prevention, early recognition and treatment of somatic problems.
The second part is MyGILL.
It provides the basis for drawing up a personalized lifestyle plan.
The result of MyGILL is an overview of the performance of patients in different lifestyle areas.
The eHealth intervention consists of an individual internet environment and is also supported by an app for mobile devices.
|
No Intervention: Care as usual
Patients will receive usual care and have unrestricted access to mental care and treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolic Syndrome Severity Score (MSSS)
Time Frame: 12 months
|
The MSSS includes the components sex, age, ethnicity, systolic blood pressure (mmHg), waistline circumference (cm), high-density lipoprotein, triglycerides and fasting blood glucose.
A lower score is considered better.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Weight (kg)
Time Frame: 12 months
|
Weight is an indication for physical health.
|
12 months
|
Length (m)
Time Frame: 1 measurement
|
Length will be measured to calculate the BMI.
|
1 measurement
|
Body Mass Index (kg/m2)
Time Frame: 12 months
|
Body Mass Index (BMI) will be determined using the measured weight and length.
A BMI between 18.5 and 25 is considered healthy.
|
12 months
|
Diastolic blood pressure (mmHg)
Time Frame: 12 months
|
A healthy score of the diastolic blood pressure lies between 60 and 80 mmHg.
|
12 months
|
Lipid profiles (mmol/l)
Time Frame: 12 months
|
LDL and total cholesterol will be determined.
For the LDL a score below 3,0 mmol/l is considered good for healthy participants, participants with additional risks for cardiovascular diseases should have a score below 2.6 mmol/l, and for participants with a cardiovascular disease the score should be below 1.8 mmol/l.
Overall, a lower LDL score is considered better.
For the total cholesterol a score below 5.0 mmol/l is considered healthy.
|
12 months
|
HbA1c (mmol/l)
Time Frame: 12 months
|
HbA1c is a measurement outcome to determine blood glucose.
A score below 53 is considered healthy.
|
12 months
|
Six-minute walk test (6MWT)
Time Frame: 12 months
|
The 6MWT is a measurement to assess physical fitness.
It measures the walking distance in 6 minutes.
A higher score indicates a longer distance walked and a better physical fitness.
|
12 months
|
International Physical Activity Questionnaire Short Form (IPAQ-SF)
Time Frame: 12 months
|
The IPAQ-SF is a 10-item self-report questionnaire where participants recall the number of days and minutes of vigorous activity, moderate activity, walking and sitting time, over the past 7 days.
A higher score indicates more physical activity.
|
12 months
|
Visual Analogue Scale (VAS)
Time Frame: 12 months
|
The VAS will be used to determine the perceived physical health, physical activity and healthy eating of the past 4 weeks on a scale from 0-100.
A higher score is considered better.
|
12 months
|
Short Form-12
Time Frame: 12 months
|
This is a generic, reliable and validated instrument to assess quality of life, containing 12 items derived from the Short Form 36 questionnaire.
Physical and mental quality of life will be measured using the physical and mental component summary of the SF-12, respectively.
A higher scores indicates a better health status.
|
12 months
|
Questionnaire about Processes of Recovery (QPR)
Time Frame: 12 months
|
The QPR is a self-report 15-item questionnaire with a score range of 0-60 (QPR total).
Higher scores are indicative of recovery.
|
12 months
|
Health of the Nation Outcome Scale (HoNOS)
Time Frame: 12 months
|
The HoNOS is a clinician-rated instrument comprising twelve items on four domains (behavioral problems, organic problems, psychological symptoms, social problems), each item ranging from 0 (no problems) to 4 (severe problems).
A lower score is considered better.
|
12 months
|
Patient Activation Measure (PAM-13)
Time Frame: 12 months
|
The questionnaire assesses the participants' self-reported knowledge, skills and confidence for health-related self-efficacy.
A higher score is considered better.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demographics
Time Frame: 12 months
|
Age, gender, ethnicity, marital status, education level, employment status, psychiatric diagnoses, diagnosesof somatic diseases, current smoking status, number of years receiving mental care, and medication use.
|
12 months
|
Treatment Inventory of Costs in Patients with psychiatric disorders (TIC-P)
Time Frame: 12 months
|
The TIC-P is a validated questionnaire designed for self-report in adult patients with a mental disorder to assess their utilization of the medical health care costs.
The TIC-P items that will be used include 14 structured questions on the volume of medical costs, e.g.
ambulatory services, private practice, and general practitioner.
A higher outcome value means more health care costs.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2023
Primary Completion (Anticipated)
October 31, 2025
Study Completion (Anticipated)
October 31, 2025
Study Registration Dates
First Submitted
August 25, 2022
First Submitted That Met QC Criteria
September 8, 2022
First Posted (Actual)
September 9, 2022
Study Record Updates
Last Update Posted (Actual)
September 9, 2022
Last Update Submitted That Met QC Criteria
September 8, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL81729.029.22
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
IPD Plan Description
Data will be intellectual property of the research team, and will be available for others in case of requests after publication of the results according to privacy regulations.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Universidad de los Andes, ChileCompleted
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
Taipei Medical University WanFang HospitalUnknownMetabolic Cardiovascular SyndromeTaiwan
-
Mayo ClinicCompleted
-
The Catholic University of KoreaCompletedMetabolic Syndrome X | Metabolic Cardiovascular Syndrome | Insulin Resistance Syndrome X | Dysmetabolic Syndrome XKorea, Republic of
-
University of HohenheimGerman Federal Ministry of Education and ResearchCompleted
-
Charite University, Berlin, GermanyRecruitingMetabolic Syndrome, Protection AgainstGermany
-
Wageningen University and ResearchPhilips Healthcare; TNO; Friesland Campina; Albert Heijn; Menzis; Smart with food; Vi... and other collaboratorsCompletedMetabolic Syndrome, Protection AgainstNetherlands
-
Cairo UniversityCompletedMetabolic Syndrome in WomenEgypt
-
Andalas UniversityHasanuddin University; Universitas Sumatera UtaraCompletedMetabolic Syndrome, Protection AgainstIndonesia
Clinical Trials on GILL eHealth
-
Dartmouth-Hitchcock Medical CenterCompletedObesity | Videoconferencing | mHealth | Technology | Behavior, HealthUnited States
-
UKK InstituteUniversity of Eastern Finland; North Karelia Hospital DistrictUnknown
-
University of MiamiNational Institute on Drug Abuse (NIDA)CompletedDrug Use | Sexual Risk Behavior | Family FunctioningUnited States
-
Dr. Danièle PacaudThe Lawson FoundationCompletedDiabetes Mellitus, Type 2Canada
-
National Defense Medical Center, TaiwanCompletedCoronary Artery Disease | Quality of Life | eHealth | Self-managementTaiwan
-
University of Alabama at BirminghamCompletedCancer | Overweight and ObesityUnited States
-
State University of New York at BuffaloUniversity of OregonActive, not recruitingAlcohol AbuseUnited States
-
Aarhus University HospitalRecruitingPersistent Physical SymptomsDenmark
-
University of Southern DenmarkOdense Patient Data Explorative NetworkRecruitingDepression, AnxietyDenmark
-
Universitat de GironaCompletedAttention Deficit-hyperactivity DisorderSpain